Lorlatinib治疗ALK或ROS1重排非小细胞肺癌:国际多中心开放标签单臂首次人体1期试验
该研究为国际多中心、开放标签、单臂、首次人体1期剂量递增试验,纳入54例晚期ALK阳性或ROS1阳性NSCLC患者,评估Lorlatinib的安全性、疗效和药代动力学。结果显示Lorlatinib具有全身和颅内活性,在多数既往接受≥2种TKI治疗失败且伴CNS转移的患者中观察到客观缓解。推荐2期剂量为100 mg每日一次。
要点
- Lorlatinib在ALK阳性患者中客观缓解率为46%(19/41,95%CI 31-63),在既往≥2种TKI治疗者中为42%(11/26,95%CI 23-63)。
- ROS1阳性患者客观缓解率为50%(6/12,95%CI 21-79),包括7例既往克唑替尼治疗者。
- 最常见治疗相关不良事件为高胆固醇血症(72%)、高甘油三酯血症(39%)、周围神经病变(39%)和周围水肿(39%)。
核心结论
- Lorlatinib在晚期ALK阳性或ROS1阳性NSCLC患者中显示出全身和颅内活性,多数患者伴CNS转移且既往≥2种TKI治疗失败。
- Lorlatinib可能成为对现有TKI(包括二代ALK TKI)耐药的ALK阳性NSCLC的有效治疗策略,正在3期随机对照试验中与克唑替尼比较。
研究设计与样本
- 国际多中心、开放标签、单臂、首次人体1期剂量递增研究,注册号NCT01970865。
- 2014年1月22日至2015年7月10日,54例患者接受至少一剂Lorlatinib,其中41例(77%)ALK阳性、12例(23%)ROS1阳性,1例ALK和ROS1状态未确认。
- Lorlatinib口服给药,剂量范围10-200 mg每日一次或35-100 mg每日两次,每个剂量至少3例患者。
- 安全性分析集为接受至少一剂Lorlatinib的患者;疗效分析集为意向治疗人群(接受至少一剂研究治疗且伴ALK或ROS1重排)。
- 主要终点为研究者评估的周期1剂量限制性毒性;次要终点包括安全性、药代动力学和客观缓解。
主要发现
- 28例(52%)患者既往接受≥2种TKI治疗,39例(72%)患者伴CNS转移。
- 54例患者中最常见治疗相关不良事件为高胆固醇血症39例(72%)、高甘油三酯血症21例(39%)、周围神经病变21例(39%)和周围水肿21例(39%)。
- 200 mg剂量组发生1例剂量限制性毒性(2级神经认知不良事件,包括言语和思维迟缓及找词困难,患者因研究药物相关毒性在周期1未服用至少16/21日规定总日剂量)。
- 未确定最大耐受剂量,推荐2期剂量选择为100 mg每日一次。
- ALK阳性患者客观缓解率为46%(19/41,95%CI 31-63);既往≥2种TKI治疗者客观缓解率为42%(11/26,95%CI 23-63)。
关键数值与推荐
- 推荐2期剂量:Lorlatinib 100 mg每日一次。
- ALK阳性患者客观缓解率:46%(19/41,95%CI 31-63)。
- ALK阳性且既往≥2种TKI治疗患者客观缓解率:42%(11/26,95%CI 23-63)。
- ROS1阳性患者客观缓解率:50%(6/12,95%CI 21-79)。
临床怎么用
- Lorlatinib在多数伴CNS转移且既往≥2种TKI治疗失败的ALK阳性或ROS1阳性NSCLC患者中显示出全身和颅内活性。
- Lorlatinib可能对现有TKI(包括二代ALK TKI)耐药的ALK阳性NSCLC患者有效,该适应症正在3期随机对照试验中进一步研究。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most patients with anaplastic lymphoma kinase (ALK)-rearranged or ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops, commonly within the CNS. This study aimed to analyse the safety, efficacy, and pharmacokinetic properties of lorlatinib, a novel, highly potent, selective, and brain-penetrant ALK and ROS1 TKI with preclinical activity against most known resistance mutations, in patients with advanced ALK-positive or ROS1-positive NSCLC. METHODS: In this international multicentre, open-label, single-arm, first-in-man phase 1 dose-escalation study, eligible patients had advanced ALK-positive or ROS1-positive NSCLC and were older than 18 years, with an Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate end-organ function. Lorlatinib was administered orally to patients at doses ranging from 10 mg to 200 mg once daily or 35 mg to 100 mg twice daily, with a minimum of three patients receiving each dose. For some patients, tumour biopsy was done before lorlatinib treatment to identify ALK resistance mutations. Safety was assessed in patients who received at least one dose of lorlatinib; efficacy was assessed in the intention-to-treat population (patients who received at least one dose of study treatment and had either ALK or ROS1 rearrangement). The primary endpoint was dose-limiting toxicities during cycle 1 according to investigator assessment; secondary endpoints included safety, pharmacokinetics, and overall response. This study is ongoing and is registered with ClinicalTrials.gov, number NCT01970865. FINDINGS: Between Jan 22, 2014, and July 10, 2015, 54 patients received at least one dose of lorlatinib, including 41 (77%) with ALK-positive and 12 (23%) with ROS1-positive NSCLC; one patient had unconfirmed ALK and ROS1 status. 28 (52%) patients had received two or more TKIs, and 39 (72%) patients had CNS metastases. The most common treatment-related adverse events among the 54 patients were hypercholesterolaemia (39 [72%] of 54 patients), hypertriglyceridaemia (21 [39%] of 54 patients), peripheral neuropathy (21 [39%] of 54 patients), and peripheral oedema (21 [39%] of 54 patients). One dose-limiting toxicity occurred at 200 mg (the patient did not take at least 16 of 21 prescribed total daily doses in cycle 1 because of toxicities attributable to study drug, which were grade 2 neurocognitive adverse events comprising slowed speech and mentation and word-finding difficulty). No maximum tolerated dose was identified. The recommended phase 2 dose was selected as 100 mg once daily. For ALK-positive patients, the proportion of patients who achieved an objective response was 19 (46%) of 41 patients (95% CI 31-63); for those who had received two or more TKIs, the proportion of patients with an objective response was 11 (42%) of 26 patients (23-63). In ROS1-positive patients, including seven crizotinib-pretreated patients, an objective response was achieved by six (50%) of 12 patients (95% CI 21-79). INTERPRETATION: In this phase 1, dose-escalation study, lorlatinib showed both systemic and intracranial activity in patients with advanced ALK-positive or ROS1-positive NSCLC, most of whom had CNS metastases and had previously had two or more TKI treatments fail. Therefore, lorlatinib might be an effective therapeutic strategy for patients with ALK-positive NSCLC who have become resistant to currently available TKIs, including second-generation ALK TKIs, and is being investigated in a phase 3 randomised controlled trial comparing lorlatinib to crizotinib (ClinicalTrials.gov, NCT03052608). FUNDING: Pfizer.
引用
- Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017. PMID: 29074098. doi:10.1016/S1470-2045(17)30680-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。